Author: Healio ophthalmology

Inotek’s phase 3 MATrX-1 trial of trabodenoson fails to meet primary endpoint

MATrX-1, a phase 3 trial of trabodenoson for the treatment of primary open-angle glaucoma or ocular hypertension, failed to achieve its primary endpoint of superiority in reduction of IOP compared with placebo at all time points, according to an Inotek Pharmaceuticals press release.The randomized, double-masked, placebo-controlled trial assessed the safety, efficacy and tolerability of three doses of trabodenoson in 303 subjects. Patients’ IOP was measured on days 14, 28, 42 and 84 at four time points during each of these days: 8 a.m., 10 a.m., 12 p.m. and 4 p.m. (Read more...)

Bag-in-the-lens a forgiving technique if explantation is needed

We present an example of a patient who underwent bag-in-the-lens cataract surgery with a monofocal lens. Six weeks postoperatively she came back complaining of visual disturbance due to residual astigmatism of –1.75 D and told us she strongly wished to be without glasses or contact lenses. Because the BIL technique offers a relatively easy method for IOL exchange, we offered to exchange the lens for a toric IOL. Surgical technique

Trefoil Therapeutics working with NIH to develop compound for Fuchs’ dystrophy

Trefoil Therapeutics is working with the National Institutes of Health to complete investigational new drug activities for a compound to treat Fuchs’ endothelial corneal dystrophy, according to a news release.Trefoil is collaborating with the NIH’s National Center for Advancing Translational Sciences to accelerate the development of the company’s lead compound, TTHX1114.

PUBLICATION EXCLUSIVE: 2016 Year in Review: Miracles do happen

For me personally, the drought of seeing the Chicago Cubs actually win the World Series and seeing the joy of my patients who have suffered even longer than me is just the icing on the cake to a great year for the ophthalmic industry in 2016. Thirteen years of having only one topical dry eye medication finally ended with an alternative for those 33 million-plus patients suffering from chronic dry eye disease. Patients with progressive keratoconus and corneal ectasia finally have a treatment other than corneal transplantation. Those patients with (Read more...)

PUBLICATION EXCLUSIVE: What measures are you taking to prepare for MIPS?

I wish I could provide an intelligent response to this question. My office manager has been busily educating herself regarding the requirements and (hopefully) getting prepared to implement the required procedural infrastructure. That being said, my level of involvement in the process remains at this superficial level, at least for now. Hopefully, my confidence in my administrative staff to “get it right” will be well founded, or we will be in for a bit of a rude awakening.